Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA, BSE: 524715) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,21,995 Cr, it ranks #14 by market cap among the 6,137 Indian listed companies on FinBizNet, and #1 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,748.00 (as of 25 Oct 2026), the share price is 14.6% below its 52-week high of ₹2,046.90 and 10.4% above its 52-week low of ₹1,583.70. The share price is up 5.4% over one year and down 9.9% over three months.
| Current Price | ₹1,748.00 |
|---|---|
| Market Cap | ₹4,21,995 Cr |
| NSE Symbol | SUNPHARMA |
| BSE Code | 524715 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 36.4 |
| Return on Equity | 14.72% |
| Return on Assets | 8.47% |
| 52-Week Range | ₹1,583.70 – ₹2,046.90 |
| 1-Year Price Change | +5.4% |
| 3-Month Price Change | -9.9% |
| Beta (1Y) | -0.15 |
| Dividend Yield | 0.57% |
| Headquarters | Mumbai, Maharashtra |
| Website | sunpharma.com |
| Revenue | ₹15,300 Cr |
|---|---|
| Net Profit | ₹2,911 Cr |
| Net Margin | 19.0% |
| EPS (Basic) | ₹12.10 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respiratory, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. It exports its p
1. Pharmaceuticals-This segment manufactures, develops, and markets branded and generic formulations, and active pharmaceutical ingredients.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Sun Pharmaceutical Industries Limited is trading at ₹1,748.00, with a market capitalisation of ₹4,21,995 Cr.
Sun Pharmaceutical Industries Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Sun Pharmaceutical Industries Limited has a P/E of 36.4 and a return on equity of 14.72%.
Sun Pharmaceutical Industries Limited is listed on the NSE under the symbol SUNPHARMA and on the BSE under the scrip code 524715.
Sun Pharmaceutical Industries Limited's share price is up 5.4% over one year and down 9.9% over three months. Its 52-week range is ₹1,583.70 to ₹2,046.90.
In Q1 FY27, Sun Pharmaceutical Industries Limited reported revenue of ₹15,300 Cr and net profit of ₹2,911 Cr, with basic EPS of ₹12.1 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.